^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

TCEAL9 overexpression

i
Other names: TCEAL9, Transcription Elongation Factor A Like 9, WEX6, WBP5, Transcription Elongation Factor S-II Protein-Like 9, Transcription Elongation Factor A Protein-Like 9, WW Domain-Binding Protein 5, TCEA-Like Protein 9, DKFZp313K1940, Pp21 Homolog, WBP-5, WW Domain Binding Protein 5, WW Domain Binding Protein 1
Entrez ID:
over1year
Elevated TCEAL9 expression is correlated with trastuzumab-based neoadjuvant chemotherapy resistance in HER2-positive breast cancer (SABCS 2022)
Objectives: To investigate the role of TCEAL9 in developing trastuzumab resistance in HER2-positive breast cancer A total of 83 patients who received paclitaxel, carboplatin and trastuzumab neoadjuvant chemotherapy in Fudan University Shanghai Cancer Center(FUSCC) from 2016 to 2018 were enrolled in this study...Overexpression of TCEAL9 was associated with lapatinib(IC50= 5.56 vs 10.90nM) and trastuzumab + pertuzumab(IC50= 745 vs 635nM) resistance in BT-474 and SK-BR-3 respectively, but has no influence in proliferation... TCEAL9 expression correlates with trastuzumab resistance and high TCEAL9 expression is associated with poor prognosis in HER2-positive breast cancer patients.
Clinical
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • TCEAL9 (Transcription Elongation Factor A Like 9)
|
HER-2 positive • TCEAL9 overexpression
|
Herceptin (trastuzumab) • carboplatin • paclitaxel • lapatinib • Perjeta (pertuzumab)